Discriminating BRAF mutations

Patent metadata

Field	Value
Publication number	US-12486539-B2
Application number	US-201916577510-A
Country	US
Kind code	B2
Filing date	Sep 20, 2019
Priority date	Feb 24, 2014
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.

First claim

What is claimed is:

1 . A kit for distinguishing a V600K mutation from a V600E mutation in the BRAF gene in a sample DNA from an individual, said kit comprising:
(a) a forward primer and a reverse primer and no more than two primers, wherein the forward primer and the reverse primer selectively generate an amplicon when a thymidine (T) to adenosine (A) mutation at position 1799 of the BRAF gene is present, wherein the primers are configured to generate an amplicon comprising a V600E (1799T>A) mutation and an amplicon comprising a V600K (1798-1799GT>AA) mutation in the BRAF gene, and (b) a restriction enzyme for distinguishing a V600K mutation from a V600E mutation in the BRAF gene, wherein the restriction enzyme digests the amplicon comprising the BRAF V600E mutation (1799T>A) and does not digest the amplicon comprising the BRAF V600K mutation (1798_1799GT>AA), wherein the forward and/or reverse primer are labeled with a detectable moiety.

2 . The kit of claim 1 , wherein the restriction enzyme recognizes a 6-base motif that matches the sequence of the BRAF gene immediately upstream of the thymidine (T) to adenosine (A) mutation at position 1799 of the BRAF gene.

3 . The kit of claim 1 , wherein the restriction enzyme is SfcI.

4 . The kit of claim 1 , wherein the detectable moiety is a fluorophore.

5 . The kit of claim 1 , wherein the sample DNA is extracted from the plasma of the individual.

6 . The kit of claim 1 , wherein the individual is a melanoma patient.

Assignees

• Quest Diagnostics Invest Llc

Inventors

• Donahue Amber C
• Peng Yen-Lin

Classifications

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title